Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Diabetes tipe 2 ditandai dengan resistensi dan defisiensi insulin, selain itu seiring dengan penuaan kejadian resistensi insulin juga semakin meningkat. Pada studi-studi klinis, resistensi insulin dan diabetes tipe 2 terbukti meningkatkan kejadian sindrom frailty pada usila. Obat antidiabetik oral metformin telah dikaitkan dengan penghambatan proses penuaan. Namun demikian, sampai saat ini belum ada data yang menunjukkan manfaat terapi metformin terhadap kejadian sindrom frailty. Penelitian ini bertujuan untuk melihat apakah ada efek protektif metformin terhadap sindrom frailty. Metodologi: Studi ini dilakukan secara kasus kontrol pada subyek berusia ≥60 tahun yang berobat di poliklinik Geriatri dan Diabetes FKUI-RSCM, bulan Maret-Juni 2013. Diagnosis frailty dilakukan dengan menggunakan indeks frailty-40 item (FI-40). Analisis statistik dilakukan dengan metode chi-square untuk analisis bivariat dan regresi logistik untuk analisis multivariat, semua data disertai dengan interval kepercayaan 95%. Hasil: Sindrom frailty didapatkan pada 25% (n=59) subyek penelitian, sedangkan pre-frail pada 72% (n=170) subyek dan sisanya fit. Metformin ditemukan mempunyai hubungan dengan sindrom frailty pada usila dengan diabetes mellitus tipe 2, yang tetap bermakna setelah dilakukan analisis multivariat (adjusted OR 0,043; IK 95% 0,019 – 0,099; p<0,001). ......Background: Type 2 diabetes (T2DM) was characterised with insulin resistance and deficiency, furthermore with advancing age the was also an increase in insulin resistance. Clinical studies has proven that insulin resistance and T2DM increase the incidence of frailty syndrome in the elderly. Oral antidiabetics metformin was associated with the inhibition of aging process. Eventhough, there was no data that showed the relationship of metformin therapy to frailty syndrome. This study aimed to explore the possibility of metformin protective effect on frailty syndrome. Methodology: This was a case control study conducted in subjects ≥60 years old who visited the Geriatrics and Diabetes outpatient clinic of Cipto Mangunkusumo National Referral Hospital between March and June 2013. Diagnosis of frailty was established using the FI-40 item criteria. Statistical analysis was done with chi-square method for bivariate and logistic regression method in multivariate analysis, all data was accompanied with 95% confidence interval. Results: Frailty syndrome was found in 25% of subjects (n=59), with median age of 72 years old (SD 6.27) and median of FI-40 item score was 0.18 (SD 0.085). Metformin was found to have a significant relationship with frailty syndrome in the elderly diabetics, which retained significant value after multivariate analysis (adjusted OR 0.043; 95% CI 0.019-0.099; p<0.001). Conclusion: Metformin was shown to have protective effect against frailty syndrome in elderly diabetics."

"

Latar Belakang: Perbaikan fungsi fisik, emosional dan kualitas hidup penderita LES harus menjadi bagian penting penatalaksanaan paripurna. Fungsi otot, yang merupakan kombinasi dari kekuatan otot dan performans fisik (Asian Working Group on Sarcopenia 2019), merupakan salah satu determinan penting kualitas hidup subyek LES. Belum ada penelitian evaluasi pengaruh fungsi otot terhadap kualitas hidup penderita LES menggunakan kuesioner Sarcopenia Quality of Life (SarQoL).

Tujuan: Evaluasi hubungan fungsi otot dengan kualitas hidup menggunakan kuesioner SarQoL pada perempuan penderita LES.

Metode: Penelitian potong lintang ini merekrut 61 subyek LES perempuan di klinik Alergi Imunologi, RSCM, secara konsekutif, fungsi otot dinilai dengan dinamometer genggam tangan Jamar (kekuatan otot) dan uji kecepatan berjalan 6 meter (performans fisik), HRQoL dinilai dengan kuesioner Sarcopenia Quality of Life (SarQoL). Kriteria penerimaan perempuan dengan LES berusia ≥18 tahun, tanpa kondisi autoimun lain dan gangguan fungsional/anatomis yang mengganggu pemeriksaan. Analisis statistik menggunakan uji t untuk analisis beda dua rerata dan analisis multivariat regresi linier untuk penyesuaian terhadap perancu.

Hasil: Rerata skor total SarQoL subyek kekuatan otot baik dan rendah didapatkan berbeda signifikan, 74,86 (9,48) vs. 65,49 (15,51) (p=0,009), tetap signifikan setelah disesuaikan usia, asupan protein, tingkat aktivitas olahraga  dan aktivitas penyakit [B -7,12; IK 95% -14,58 –(-1,20)]. Rerata skor total SarQoL subyek dengan kecepatan berjalan baik dan rendah tidak didapatkan berbeda signifikan 70,67 (11,08) vs. 70,72 (13,56) (p=0,993).

Simpulan: Terdapat hubungan signifikan antara kekuatan otot dan kualitas hidup terkait kesehatan menurut SarQoL pada perempuan penderita LES

......

Background: Improvement of physical, emotional function and quality of life of SLE patients, should be an important part of holistic clinical management. Muscle function, a combination of muscle strength and physical performance (Asian Working Group on Sarcopenia 2019), was an important determinant of quality of life in lupus patients. There was no study aimed at evaluating the impact of mucscle function on SLE patient’s quality of life using Sarcopenia Quality of Life (SarQoL) questionnaire.

Aim: This study was conducted to evaluate the relationship of muscle function and SarQoL score in women with SLE.

Methods: This cross-sectional study recruited 61 women with SLE in Allergy-Immunology Clinic of Cipto Mangunkusumo Hospital consecutively, muscle function was measured with Jamar handheld-dynamometer and 6 meter walk test, HRQoL was measured with Sarcopenia Quality of Life (SarQoL) questionnaire. Acceptance criteria include women ≥18 years old with SLE, and not with other autoimmune disease nor functional/anatomical dysfunction that disturb measurements. Statistical analysis was conducted with t-test for mean difference and linier regression was used to adjust confounders.

Results: The difference of total SarQoL score in subjects with good and low muscle strength was found to be significant; 74.86 (9.48) vs. 65.49 (15.51) (p=0.009), statistically significant after adjusments with age, protein intake, physical acitvity level and disease activity [B -7.12; 95% CI -14.58 –(-1.20)]. The difference of total SarQoL score in subjects with good and low physical performance was found to be not significant 70.67 (11.08) vs. 70.72 (13.56) (p=0.993).

Conclusion: There was a significant association between muscle strength and HRQoL according to SarQoL in women with SLE

"